Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication of diabetes, in which the reduced effective action of circulating insulin combined with upregulation of counterregulatory hormones leads to hyperglycemia and uncontrolled oxidation of fatty acids into ketone bodies. This results in hyperosmolality and usually a severe anion gap metabolic acidosis.
Symptoms have a rapid onset (< 24 hours) and include polyuria, polydipsia, lethargy, and abdominal pain. The hyperosmolality can cause neurologic symptoms, such as mental obtundation and coma.
Patients taking sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg, for diabetes mellitus type 2) may be at increased risk for DKA.
The treatment of DKA includes the correction of electrolyte and fluid abnormalities along with the administration of insulin.
ICD10CM: E13.10 – Other specified diabetes mellitus with ketoacidosis without coma
SNOMEDCT: 420422005 – Ketoacidosis in diabetes mellitus
Below is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.